drugset / Trial / NCT03223103
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Phase 1
Active not recruiting
13 enrolled
Adilia Hormigo
NovoCure Ltd. · collabOncovir, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields). The study is designed to determine whether this treatment combination is well tolerated and safe.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2029-05-12
- Completion
- 2029-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hiltonol | Other / unclassified | 100 ug | — |
| Subject | Peptides | Peptide | — | — |